参考文献/References:
[1]张静洁,郑志兵,李松.多发性骨髓瘤的靶向治疗[J].沈阳药科大学学报,2017,34(8):723-728.[2]张津京,李艳.初诊多发性骨髓瘤合并肾功能不全患者的临床特点和疗效分析[J].中国医科大学学报,2016,45(6):494-498.[3]杜鹃,侯健.《中国多发性骨髓瘤诊治指南(2015年修订)》诊断部分解读[J].中华内科杂志,2016,55(2):91-92.[4]Liu J,Liu W,Mi L,et al.Union for China Lymphoma Investigators of the Chinese Society of Clinical Oncology; Union for China Leukemia Investigators of the Chinese Society of Clinical Oncology. Incidence and mortality of multiple myeloma in China, 2006-2016: an analysis of the Global Burden of Disease Study 2016[J].J Hematol Oncol,2019,12(1):136.[5]McKinnon KM.Flow Cytometry: An Overview[J].Curr Protoc Immunol,2018(120):5.1.1-5.1.11.[6]Rihova L,Vsianska P,Bezdekova R,et al.Minimal Residual Disease Assessment in Multiple Myeloma by Multiparametric Flow Cytometry[J].Klin Onkol,2017,30(Supplementum2):21-28.[7]Flores-Montero J,Sanoja-Flores L,Paiva B,et al.Next Generation Flow for highly sensitive and standardized detection of minimal residual disease in multiple myeloma[J].Leukemia,2017,31(10):2094-2103.[8]Rajkumar SV.Multiple myeloma: Every year a new standard?[J].Hematol Oncol,2019(37 Suppl 1):62-65.[9]Flores-Montero J,de Tute R,Paiva B,et al.Immunophenotype of normal vs. myeloma plasma cells: Toward antibody panel specifications for MRD detection in multiple myeloma[J].Cytometry B Clin Cytom,2016,90(1):61-72.[10]Alaterre E,Raimbault S,Garcia JM,et al.Automated and simplified identification of normal and abnormal plasma cells in Multiple Myeloma by flow cytometry[J].Cytometry B Clin Cytom,2018,94(3):484-492.[11]Skerget M,Skopec B,Zadnik V,et al.CD56 Expression Is an Important Prognostic Factor in Multiple Myeloma Even with Bortezomib Induction[J].Acta Haematol,2018,139(4):228-234.[12]Drent E,Poels R,Ruiter R,et al.Combined CD28 and 4-1BB Costimulation Potentiates Affinity-tuned Chimeric Antigen Receptor-engineered T Cells[J].Clin Cancer Res,2019,25(13):4014-4025.[13]Wang J,Zheng Y,Tu C,et al.Identification of the immune checkpoint signature of multiple myeloma using mass cytometry-based single-cell analysis[J].Clin Transl Immunology,2020,9(5):e01132.[14]Ceran F,Falay M,Dagdas S,et al.The Assessment of CD56 and CD117 Expressions at the Time of the Diagnosis in Multiple Myeloma Patients[J].Turk J Haematol,2017,34(3):226-232.[15]Wang H,Zhou X,Zhu JW,et al.Association of CD117 and HLA-DR expression with shorter overall survival and/or progression-free survival in patients with multiple myeloma treated with bortezomib and thalidomide combination treatment without transplantation[J].Oncol Lett,2018,16(5):5655-5666.[16]Shi J,Sun K,Zhu ZM,et al.Prognostic significance of CD56 and CD117 expression in patients with newly diagnosed multiple myeloma treated with bortezomib-based first-line therapy[J].Chin J Hematol,2019,40(8):693-696.[17]Huang B,Li J,Liu J,et al.CD20-positive multiple myeloma: can conventional chemotherapy still be used to achieve ideal outcome for these patients?[J].Leuk Lymphoma,2016,57(2):335-340.[18]Muchtar E,Gertz MA.The colorful landscape of multiple myeloma[J].Leuk Lymphoma,2019,60(9):2099-2100.[19]刘帅,李曌博,张帆,等.37例CD45阳性的多发性骨髓瘤浆细胞免疫学表型特征[J].检验医学,2017,32(2):76-80.[20]朱杰,赵成艳,王敏,等.多发性骨髓瘤免疫表型及胞浆轻链检测的临床意义[J].实用检验医师杂志,2013,17(6):1068-1071.[21]Moore S,Suttle JM,Nicola M.Cytoplasmic Immunoglobulin Light Chain Revelation and Interphase Fluorescence In Situ Hybridization in Myeloma[J].Methods Mol Biol,2017(1541):127-142. [22]Papanikolaou X,Alapat D,Rosenthal A,et al.The flow cytometry-defined light chain cytoplasmic immunoglobulin index and an associated 12-gene expression signature are independent prognostic factors in multiple myeloma[J].Leukemia,2015,29(8):1713-1720.
相似文献/References:
[1]贾海英,黄睿,王玲玲,等.多发性骨髓瘤患者淋巴细胞亚群变化对免疫功能的影响研究[J].医学信息,2018,31(01):147.[doi:10.3969/j.issn.1006-1959.2018.01.057]
JIA Hai-ying,HUANG Rui,WANG Ling-ling,et al.The Effect of Lymphocyte Subgroup Changes on Immune Function in Patients with Multiple Myeloma[J].Medical Information,2018,31(02):147.[doi:10.3969/j.issn.1006-1959.2018.01.057]
[2]岳永威,孔令军.儿童急性早幼粒细胞白血病的免疫表型特点分析[J].医学信息,2021,34(23):36.[doi:10.3969/j.issn.1006-1959.2021.23.010]
YUE Yong-wei,KONG Ling-jun.Analysis of Immunophenotypic Characteristics of Children with Acute Promyelocytic Leukemia[J].Medical Information,2021,34(02):36.[doi:10.3969/j.issn.1006-1959.2021.23.010]
[3]祝 静,龙思琪,蒋 瑶,等.川东北地区MM患者骨髓瘤细胞免疫表型特征及其临床意义[J].医学信息,2021,34(10):88.[doi:10.3969/j.issn.1006-1959.2021.10.024]
ZHU Jing,LONG Si-qi,JIANG Yao,et al.Immune Phenotype Characteristics and Clinical Significance of Myeloma Cells in Patients with MM in Northeastern Sichuan[J].Medical Information,2021,34(02):88.[doi:10.3969/j.issn.1006-1959.2021.10.024]
[4]徐晓雪.CD4单阳参考品辅助检测九色标记人血样品的流式分析技术[J].医学信息,2021,34(20):90.[doi:10.3969/j.issn.1006-1959.2021.20.022]
XU Xiao-xue.Flow Pattern Analysis Technique for CD4 Single-positive Reference Substance-assisted Detection of Nine-color Labeled Human Blood Samples[J].Medical Information,2021,34(02):90.[doi:10.3969/j.issn.1006-1959.2021.20.022]
[5]赵崇山,王宁方.脾脏硬度联合流式细胞术在急性髓系白血病微小残留病监测中的意义[J].医学信息,2022,35(05):121.[doi:10.3969/j.issn.1006-1959.2022.05.031]
ZHAO Chong-shan,WANG Ning-fang.The Significance of Spleen Stiffness Measurement Combine with Flow Cytometry in Acute Myeloid Leukemia Minimal Residual Disease[J].Medical Information,2022,35(02):121.[doi:10.3969/j.issn.1006-1959.2022.05.031]
[6]雷 伟,李智伟,郭玉娟,等.人工神经网络在流式细胞术数据分析中的应用[J].医学信息,2023,36(18):74.[doi:10.3969/j.issn.1006-1959.2023.18.013]
LEI Wei,LI Zhi-wei,GUO Yu-juan,et al.Application of Artificial Neural Networks in Flow Cytometry Data Analysis[J].Medical Information,2023,36(02):74.[doi:10.3969/j.issn.1006-1959.2023.18.013]
[7]摆文丽,农卫霞,李智伟,等.FCM数据细胞亚群分类和标注的自动化研究[J].医学信息,2024,37(06):78.[doi:10.3969/j.issn.1006-1959.2024.06.013]
BAI Wen-li,NONG Wei-xia,LI Zhi-wei,et al.Automatic Classification and Labeling of Cell Subsets in FCM Data[J].Medical Information,2024,37(02):78.[doi:10.3969/j.issn.1006-1959.2024.06.013]